Osterholm MT. Author interviews with Michael Osterholm. May 3 and Aug 2, 2007 WHO. Global Advisory Committee on Vaccine Safety, 6-7 June 2006. Meeting report released Jun 14, 2006 [Full text] Schwartz SI. Atomic audit : the costs and consequences of U.S. nuclear weapons since 1940. Washington, DC: Brookings Institution Press, 1998 Fedson DS. Author interview with David Fedson. Jun 19, 2007 CDC. State-specific influenza vaccination coverage among adults aged >/= 18 years—United States, 2003-04 and 2005-06 influenza seasons. MMWR 2007 Sep 21;56(37):953-9 [Full text] HHS. HHS awards two contracts to expand domestic vaccine manufacturing capacity for a potential influenza pandemic. Jun 14, 2007 [Full text] Fauci AS. Seasonal and pandemic influenza preparedness: science and countermeasures. J Infect Dis 2006 Nov 1;194(suppl 2):S73-6 [Full text] CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005 Jul 29;54(RR08):1-40 [Full text] Osterholm MT. Preparing for the next pandemic. Foreign Aff 2005 Jul/Aug;84(4) [Full text] Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007 Feb 15;256(7):685-96 [Abstract] WHO. Projected supply of pandemic influenza vaccine sharply increases. Oct 23, 2007 [Press release] Keitel W. A phase I-II, randomized, controlled, dose-ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine given alone or with aluminum hydroxide to healthy adults. Presented at the Options for the Control of Influenza VI meeting, Toronto, Jun 2007 Lowen AC, Mubareka S, Tumpey TM, et al. The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci 2006 June 27;103(26):9988-92 [Full text] Wood JM. International standards for H5N1 antibodies. Presented at the 3rd WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials, Geneva, Feb 15-16, 2007 [Full text] Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005 Apr 15;191(8):1210-5 [Full text] Goodman J. How fast can a new vaccine for an emerging respiratory virus be developed and available for use? Presented at the International Conference on Emerging Infectious Diseases, Atlanta, GA, Mar 22, 2006 Leroux-Roels K, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007 Aug 18;370(9587):580-9 [Abstract] Novartis. Novartis gains European approval for its innovative flu vaccine Optaflu. Jun 13, 2007, news release Poland GA. Vaccines against avian influenza—a race against time. (Editorial) N Engl J Med 2006 Mar 30;354(13):1411-3 [Full text] Stephenson I, Gust I, Pervikov Y, et al. Development of vaccines against influenza H5. Lancet Infect Dis 2006 Aug;6(8):458-60 Fedson DS, Dunnill P. New approaches to confronting an imminent influenza pandemic. (Commentary) Perm J 2007 Summer;11(3):63-9 [Full text] NIAID (National Institute of Allergy and Infectious Diseases). Report of the Blue Ribbon Panel on Influenza Research. Bethesda, Md., Sep 11-12, 2006. Posted Jun 2007 [Full text] Kreijtz JH, Bodewes R, van Amerongen G, et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007 Jan 8;25(4):612-20 [Abstract] Protein Sciences Corp. Influenza vaccines under development. 2007 [Web page] BD. Author interview with George Goldman, Senior Director, Hypodermic Divison, BD Medical Surgical Systems. Jul 25, 2007 Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 2004 Oct 1;39(7):920-7 [Full text] GAO. Flu vaccine: steps are needed to better prepare for possible future shortages. Testimony by Janet Heinrich before US Senate Special Committee on Aging. GAO-01-786T. May 30, 2001 [Full text] FDA. Vaccines and Related Biological Products Advisory Committee meeting transcript. Feb 27, 2007 [Full text] Petrovsky N. New-age vaccine adjuvants: friend or foe? BioPharm Int Aug 2, 2007 WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO, 10 Sep 2007 Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001 Jun 16;357(9272):1937-43 [Abstract] Gosling FG. The Manhattan Project: making the atomic bomb. Oak Ridge, TN: US Department of Energy History Division, Jan 1999 Germann TC, Kadau K, Longini IR, et al. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci 2006 Apr 11;103(15):5935-40 [Abstract] Grady D. With few suppliers of flu shots, shortage was long in making. New York Times. Oct 17, 2004 [Full text] GSK (GlaxoSmithKline). Backgrounder: Egg-based vs. cell-based influenza vaccine production. 2005 GSK. GlaxoSmithKline awarded $63 million HHS contract for pandemic vaccine research and development. Jan 17, 2007 [Press release] Smith GJD, Fan XH, Wang J, et al. Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci 2006 Nov 7;103(45):16936-41 [Abstract] Working Group for Pandemic Influenza Preparedness. Letter to Congress. May 23, 2006 Heilman C. Author interviews with Carole Heilman. Sep 13 and Sep 24, 2007 Novartis. Novartis receives US government contract to further develop a novel antigen technology that could extend vaccine supplies in a pandemic outbreak. Jan 17, 2007, news release [Full text] Vajo Z, Kosa L, Visontay I, et al. Inactivated whole virus influenza A (H5N1) vaccine. (Letter) Emerg Infect Dis 2007 May;13(5) (published online Mar 29) [Full text] McKenna M. System for global pandemic vaccine development challenged. Minneapolis, MN: CIDRAP News, Feb 6, 2007 [Full text] IDSA (Infectious Diseases Society of America). Pandemic and seasonal influenza principles for US action. Released Jan 25, 2007 [Full text] ECDC (European Centre for Disease Prevention and Control). ‘Pre-pandemic’ vaccines might offer protection but uncertainties remain. Sep 20, 2007 [Press release] IOM. Vaccines for the 21st century. Released Mar 1999 [Full text] HHS (Department of Health and Human Services). HHS awards contracts totaling more than $1 billion to develop cell-based influenza vaccine. May 4, 2006 [Full text] IOM (Institute of Medicine). New vaccine development. 1985;1 The series: The pandemic vaccine puzzle FDA. Guidance for industry: Clinical data needed to support the licensure of pandemic influenza vaccines. May 31, 2007 [Full text] GAO (Government Accountability Office, formerly General Accounting Office). Flu vaccine: recent supply shortages underscore ongoing challenges. Testimony by Janet Heinrich before House Subcommittee on Health, Subcommittee on Oversight and Investigations, and Committee on Energy and Commerce. GAO-05-177T. Nov 18, 2004 [Full text] McKenna M. Virus ownership claims could disrupt flu vaccine system. Minneapolis, MN: CIDRAP News. Jun 19, 2007 [Full text] Palkonyay L. Personal communication from Laszlo Palkonyay, MD, medical officer, WHO Initiative for Vaccine Research. Oct 25, 2007 Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006 Sep 16;368(9540):991-7 [Abstract] Lipatov AS, Webby RJ, Govorkova EA, et al. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 2005 Apr 15;191(8):1216-20 [Full text] Bosch Technologies. Author interview with Eric Isberg, Jack Lysfjord, and Tony Miller. Aug 3, 2007 CDC. Isolation of avian influenza A(H5N1) viruses from humans—Hong Kong. May-December 1997. MMWR 1997 Dec 19;46(50):1204-7 [Full text] Editor’s note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007 Apr 11;297(14):1577-82 [Abstract] Trust for America’s Health/Infectious Diseases Society of America. Pandemic influenza: the state of the science. Oct 2006 [Full text] Monto A. Author interview with Arnold Monto. Aug 2, 2007 Trust for America’s Health. Flu spending update: pandemic planning and resource allocation. 2007 Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis 2006 Jan;12(1):66-72 [Full text] NIH (National Institutes of Health). Flu 2001-2008 estimated budget numbers spreadsheet, compiled for the author by NIH press office. 2007 Rosenwald MS. FluMist gets a needed boost: refrigerated version cleared. Washington Post. Jan 9, 2007 [Full Text] ECDC. Technical report: Expert advisory groups on human H5N1 vaccines: scientific questions. Aug 2007 [Full text] Govorkova EA, Webby RJ, Humberd J, et al. Immunization with reverse-genetics–produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006 Jul 15;194(2):159-67 [Full text] Thomas A, Guldager N, Hermansen K. Pandemic flu preparedness: a manufacturing perspective. BioPharm Int 2007 Aug (supp) (published online Aug 2) Goodman J. Considerations in the pre- and early pandemic use of influenza vaccine. Presented at FDA Center for Biologics Evaluation and Research Vaccines and Related Biological Products Advisory Committee Meeting, Gaithersburg, MD, Feb 27, 2007 Longini IM, Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science 2005 Aug 12;309(5737):1083-7 [Abstract] Part 1: Flu research: a legacy of neglectPart 2: Vaccine production capacity falls far shortPart 3: H5N1 poses major immunologic challengesPart 4: The promise and problems of adjuvantsPart 5: What role for prepandemic vaccination?Part 6: Looking to novel vaccine technologiesPart 7: Time for a vaccine ‘Manhattan Project’?Bibliography [you are here] Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. (Letter) Nature 2006 Jul 27;442(7101):448-52 [Abstract] WHO. Global pandemic influenza action plan to increase vaccine supply. Released Oct 23, 2006 [Full text] Sanofi Pasteur. Sanofi Pasteur announces completion of construction of new U.S. influenza vaccine manufacturing facility. Jul 20, 2007, news release [Full text] Hoffenbach A. Update of Sanofi Pasteur EU pandemic vaccine clinical development. Presented at the 3rd WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Geneva, Feb 14, 2007 [Full text] Santoli J. Influenza vaccine distribution data and use of data during the 2006-07 season. Presented at the National Influenza Vaccine Summit, Atlanta, Apr 2007 [Presentation] Stephenson I, Gust I, Kieny MP, et al. Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis 2006 Feb;6(2):71-2 Riley S, Wu JT, Leung GM. Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate. PLoS Med 2007 Jun;4(6):e218 [Full text] Strikas R. Pandemic influenza vaccine supply issues. Presented at the National Vaccine Advisory Committee Pandemic Influenza Working Group Meeting, Washington, DC, Apr 20, 2005 Kotalik J. Preparing for an influenza pandemic: ethical issues. Bioethics 2005 Aug;19(4):422-31 [Abstract] Fedson DS, Dunnill P. From scarcity to abundance: pandemic vaccines and other agents for “have not” countries. (Commentary) J Public Health Policy 2007;28(3):322-40 [Abstract] Acambis PLC. Acambis’ universal influenza vaccine enters phase 1 trial. Jul 17, 2007 Wood JM. Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza Other Respir Virus 2007 Jan;1(1):5-9 [Abstract] Bresson JL, Perrone C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006 May 20;367(9523):1657-64 [Abstract] Treanor JJ (for Goji NA, Nolan C, Hill H, et al). Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. Presented at 3rd WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Geneva, Feb 15-16, 2007 [Full text] Wood JM. Author interview with John Wood. Jun 18, 2007 Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis 2003 Jun 15;36(12):1552-61 [Full text] Working Group for Pandemic Influenza Preparedness. Letter to Congress. Nov 10, 2005 [Full text] Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007 April;7(4):267-78 [Abstract] OIE (World Organization for Animal Health). Update on avian influenza in animals (type h5), 15 Sep 2007 [Link updated regularly] Frist W. The Manhattan project for the 21st century. Presented at Nantucket Atheneum, Nantucket, MA, Aug 3, 2005 [Full text] GAO. Flu vaccine: supply problems heighten need to ensure access for high-risk people. Report to Congressional Requestors. GAO-01-624. May 15, 2001 [Full text] Treanor JJ, Schiff GM, Couch RB, et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006 May 1;193(9):1223-8 [Full text] Novartis. Flu Cell Culture Technology: The Next Frontier. 2006 Royal Society. Pandemic influenza: science to policy. Nov 2006 [Full text] Hehme N. GSK’s pandemic vaccine development: from 1st to to 2nd generation candidate vaccines. Presented at the 3rd WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Geneva, Feb 15-16, 2007 [Full text] FDA. Guidance for industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. May 31, 2007 [Full text] WHO. WHO consultation on priority public health interventions before and during an influenza pandemic. Apr 27, 2004 Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006 Mar 30;354(13):1343-51 [Full text] Stephenson I, Nicholson KG, Wood JM, et al. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004 Aug;4(8):499-509 [Abstract] Schwartz B, Gellin B. Vaccination strategies for an influenza pandemic. (Commentary) J Infect Dis 2005 Apr 15;191(8):1207-9 [Full text] EMEA (European Medicines Agency). Guideline on adjuvants in vaccines for human use. Jan 20, 2005 [Full text] Fraser C. Influenza pandemic vaccines: spread them thin? PLoS Med 2007 Jun;4(6):e228 [Full text] Haaheim L. Vaccines for an influenza pandemic: scientific and political challenges. Influenza Other Respir Virus 2007;1(2):55-60 [Abstract] Lauerman J. Glaxo, Novartis, hurt by drug setbacks, may lose flu-shot race. Bloomberg News. Aug 23, 2007 [Full text] Working Group for Pandemic Influenza Preparedness. Letter to Congress. Jun 5, 2007 Poland GA. Author interview with Gregory Poland. Aug 1, 2007 Kresse H. Author interview with Hedwig Kresse. Aug 2, 2007 Zangwill K, Campbell J, Noah D, et al. Evaluation of a third dose of subvirion H5N1 influenza vaccine (rgA/Vietnam/1203/04 x PR8) in healthy adults. Presented at Options for the Control of Influenza VI, Toronto, Jun 17-23, 2007 Iomai. Iomai awarded government contract, totaling $128 million, to develop dose-sparing patch for use in an influenza pandemic. Jan 17, 2007 [Press release] Crosby AW. America’s forgotten pandemic: the influenza of 1918. Cambridge [England]; New York, Cambridge University Press, 1989
Topics : The app, which is not available in China, has sought to distance itself from its Chinese roots to appeal to a global audience and has emphasized its independence from China.Pompeo’s remarks also come amid increasing US-China tensions over the handling of the coronavirus outbreak, China’s actions in Hong Kong and a nearly two-year trade war.TikTok, a short-form video app owned by China-based ByteDance, was recently banned in India along with 58 other Chinese apps after a border clash between India and China.Reuters reported late on Monday that TikTok would exit the Hong Kong market within days, deciding to do so after China’s establishment of a sweeping new national security law for the semi-autonomous city. Secretary of State Mike Pompeo said late on Monday that the United States is “certainly looking at” banning Chinese social media apps, including TikTok.”I don’t want to get out in front of the President (Donald Trump), but it’s something we’re looking at,” Pompeo said in an interview with Fox News.US lawmakers have raised national security concerns over TikTok’s handling of user data, saying they were worried about Chinese laws requiring domestic companies “to support and cooperate with intelligence work controlled by the Chinese Communist Party.”
The four coalition partners making up the Netherlands’ new government have said they aim to conclude an accord for a new pensions contract early in 2018.Their governing agreement – presented yesterday – made clear that the cabinet would also provide clarity about how a transition from average to age-related “degressive” pensions accrual would take shape.The necessary legislation must be approved by parliament by 2020 before the implementation of the new arrangements can start.In the governing accord, the coalition partners – the liberals (VVD), the Christian democrats (CDA), liberal democrats (D66) and small religious-right party CU – said that they would increase the freedom of choice for pension fund participants by introducing the option of a lump sum at retirement. They also promised that the government would contribute to the transition costs – largely as a compensation for the affected participants – to degressive pensions accrual. Costs have been estimated at between €25bn and €100bn.The coalition agreement also indicated that the new cabinet, which is still to be constructed, would keep the principle of mandatory participation. This comes despite three of the coalition partners initially advocating freedom to pick a pensions provider.The four parties also said that they would facilitate the collective transition of existing pension claims into individual pension assets.The new pensions contract is most likely to comprise individual pensions accrual combined with a certain amount of collective risk sharing, and is to be added to the existing range of pension arrangements.Recently, the coalition partners said they wanted to enable the social partners of employers and workers – which have been discussing the issue in the Social and Economic Council (SER) for the past two years – to come up with their own proposals.Commenting on the government’s plans, the Netherlands’ Bureau for Economic Policy Analysis (CPB), said that abolishing average pensions accrual would be bad for purchasing power. It estimated that combined pension contributions would have to rise by €1bn.The coalition agreement also said that deploying pension assets to pay off a mortgage would not be possible for the time being. This option would be looked at after the reform of the pensions system has been completed, the parties said.The governing accord did not mention plans to further limit the tax-facilitated pensions accrual either. Currently, the annual tax-friendly accrual is 1.875% for a salary of up to €103,317.The agreement explicitly stated that the new government rejected additional European pension rules, emphasising that “the pensions system would remain a local competence”.The new coalition government must operate cautiously, as it has the smallest possible majority in parliament.As a consequence, three of the four political leaders won’t take up a ministerial post, but instead will stay on as chair of their respective parliamentary parties.The new cabinet will again be headed by VVD leader Mark Rutte, who has been prime minister for the past two Dutch parliaments.
While teams have played behind closed doors for the odd game, it is rather unusual for league matchups. read also:Eagles’ stars in Epl may undergo bi-weekly covid-19 test It is unclear how empty stadiums would impact the home advantage that teams usually enjoy in league fixtures. There is a league meeting on Friday to work on plans for a return to competitive action sometime in June. FacebookTwitterWhatsAppEmail分享 Promoted ContentTV Characters Who Hated Each Other But Later Became FriendsTop 10 Most Romantic Nations In The World5 Of The World’s Most Unique Theme ParksTop 8 Most Fun Sylvester Stallone MoviesCouples Who Celebrated Their Union In A Unique, Unforgettable Way7 Universities In The World Where Education Costs Too Much9 Facts You Should Know Before Getting A TattooTop 9 Scariest Haunted Castles In Europe5 Of The World’s Most Unique Theme ParksFantastic-Looking (and Probably Delicious) Bread ArtBest & Worst Celebrity Endorsed Games Ever Made10 Risky Jobs Some Women Do Premier League is making plans to stage friendly games so players can prepare before competitive action begins. It is not only going to help the players with their fitness, but these matches will be used as a trial of football without crowds. The Daily Mailreports that the league will be organising these friendlies at stadiums in accessible areas before the 19-20 season resumes. “You can do all the training in the world but it just doesn’t replicate the realism of a match,” one coach at a top-flight club told the source.Advertisement Loading…
The committee has so far met with the commission on revenue allocation and treasury as they seek to find a middle ground.Also Read SRC moves to address pay disparities After nine attempts at unlocking the stalemate, Senators opted to appoint a 12 member team to find a suitable formula that will solve the puzzle on how to share out Ksh 316 billion among the 47 counties.Also Read Uhuru extends curfew ahead of his address Tuesday next weekThe team will be co-chaired by Bungoma Senator Moses Wetangula and his Nairobi counterpart Johnson Sakaja.The committee will include Senators Mutula Kilonzo Jnr (Makueni), Mahamud Mohamed (Mandera), Steward Madzayo (Kilifi), Kipchumba Murkomen (Elgeyo Marakwet), Susan Kihika (Nakuru), Samson Cherargei (Nandi), Moses Kajwang (Homa Bay), Anwar Oleitiptip (Lamu), Ledama Ole Kina (Narok) and John Kinyua (Laikipia). The journey towards finding an acceptable formula to share revenue among counties appears far from over after the 12 member Senate team tasked with building a consensus failed to solve the deadlock on Monday.This effectively dealt a blow to a planned sitting of the Senate on Tuesday to dispense with the matter that has sharply divided the House.Also Read KUPPET calls on parents to prepare for early reopeningThe legislators spent hours in a closed door meeting for the better part of the day. Sources at the committee say the 12 Senators are yet to settle on an appropriate formula but says the committee is hopeful that by Thursday there will be a consensus on the divisive shilling.Get breaking news on your Mobile as-it-happens. SMS ‘NEWS’ to 20153
Second to Henderson’s ‘black aeroplane’ at Aintree was the Colin Tizzard-trained Cue Card, and he too still holds an engagement. Henderson has an alternative to Sprinter Sacre in Finian’s Rainbow, the former champion chaser who was fourth to his illustrious stablemate in the two-and-a-half-mile Melling Chase at Aintree. De Bromhead also has a second string to his bow in the shape of Days Hotel. Foildubh, Mad Moose and Noble Prince complete the octet. Sprinter Sacre stood his ground among eight entries remaining in the Boylesports.com Champion Chase at Punchestown on Tuesday. Press Association Nicky Henderson’s brilliant seven-year-old has again been imperious this season, taking his unbeaten run over fences to nine with victories at Sandown, twice at Cheltenham and most recently Aintree. Some 19 lengths behind Sprinter Sacre in the Queen Mother Champion Chase was Sizing Europe, and Henry de Bromhead’s 11-year-old, winner of this race 12 months ago, could reoppose.
King called time on his 13-year professional career last summer after finally admitting defeat in his battle against a chronic knee injury. After announcing his decision, King conceded there was no chance of him ever playing again, but that did not stop Redknapp attempting to persuade the 32-year-old to lace up his boots for one more season. Ledley King has revealed Harry Redknapp tried to persuade him to come out of retirement to play for QPR last season. With QPR struggling at the foot of the relegation zone, the Hoops boss needed all the help he could get, but King, who spent all his career at Spurs, could not accept the offer. “I believe (Redknapp) tried to (get me to come out of retirement), but he didn’t manage to get hold of me,” King told Press Association Sport at the launch of Vodafone 4G in Trafalgar Square. “I wouldn’t have done it though. I played at Tottenham my whole life and it would have been a bit silly to try and come back knowing I can’t do what I want, play the way I like to play. I have barely kicked a ball since I retired. “And I also have got such a great affiliation with Tottenham, so I would like to leave it there.” King was regarded as one of the best centre-backs of his generation, but his persistent knee troubles meant he only played 21 times for England. He has become an ambassador for Spurs since retiring, travelling the globe to promote the club and several of their initiatives. Being around the team, and youth coaches Tim Sherwood and Les Ferdinand, has ignited his desire to coach in the future. “Yeah, that is a definite possibility,” King said when asked whether he would like to coach. “Last season I did a little bit and this season I will try and push on with it a little bit more. “I have seen the likes of Tim Sherwood and Les Ferdinand working wonders at the club with the Under-21s and it intrigues me. I am around good people to learn from.” Press Association
The Spain international, who played the first half of City’s friendly victory over Hearts on Friday, has broken the fifth metatarsal in his right foot. “I want to let you know that its going to be hard for the next few months, I fractured my 5th metatarsal and will be out a few months,” Negredo wrote on his Instagram account with an accompanying picture of him wearing a protective boot. Manchester City striker Alvaro Negredo expects to be sidelined “for a few months” after breaking his foot. “I will be back stronger than ever. I will return with a vengeance.” Negredo appeared to sustain the injury shortly after setting up City’s opening goal against Hearts, scored by Scott Sinclair, with a brilliant through-ball. The 28-year-old joined City from Sevilla a year ago in a £16million-plus deal and quickly became a fans’ favourite after making an immediate impact. He scored an impressive 23 goals in his first 33 games in all competitions, including City’s first Champions League hat-trick in the 5-2 win over CSKA Moscow. However, from mid-January onwards he began to struggle and in 16 subsequent matches up to the end of the season he failed to score, which put additional pressure on City’s other strikers and midfielder Yaya Toure to come up with the goals which secured them a second Premier League title in three years. Earlier in the summer City manager Manuel Pellegrini was reported to be willing to listen to offers for the striker and Negredo was linked with a move back to Spain to rejoin former club Real Madrid for a second time, but his injury setback looks to have ended that prospect. Press Association
Press Association City moved level on points with Barclays Premier League leaders Chelsea thanks to a brace from David Silva and Yaya Toure’s fourth goal in six matches. But Warnock thought his team could have taken something from the game had they not wrongly had a goal chalked off while the hosts were 2-0 up. “I think we could have come away with something. That’s why I am bitterly disappointed because we worked so hard all week and it’s nothing to do with us why that goal gets chalked off. We could have put them under the cosh for 20 minutes. “I wish I was still working in the media so I could say what I want without getting fined.” City had eight attempts in the first half, but Palace goalkeeper Julian Speroni did not have a save to make because of City’s wayward finishing. The hosts improved after the break though and Silva put them ahead with a deflected shot that looped over Speroni. The Spaniard converted Aleksandar Kolarov’s square pass to double City’s lead before Toure sealed the win with nine minutes to go. “I was always confident (we would win),” Pellegrini said. “We had the patience to try to create the space. We did not allow them to have not one counter attack. “I was absolutely sure we were going to score and in the end we scored three goals against a difficult team that defended very well.” Pellegrini and his players came in for criticism at the start of the season for being unable to keep pace with Chelsea, but after a run of six straight league wins City are now equal on points with the Blues, who play Stoke on Monday. Pellegrini has been happy to see Toure return to form, but also pointed others out for praise following the win. “Yaya was very criticised at the beginning of the season but it was not only Yaya (who) was not putting in his best performance,” the Chilean said. “I said then, when our midfielders like Yaya, Fernandinho, (Samir) Nasri and Silva return to their normal performance, the team will play again the way we normally do. “I think that all of them this moment are in a very good moment, especially Fernandinho, Yaya and Nasri. They are playing regular and David is returning from a long injury with his knee the way he knows how to play.” Pellegrini was sure City would recover from their poor start to the campaign. “We are in a good moment,” said Pellegrini, who had to play James Milner up front because Sergio Aguero, Stevan Jovetic and Edin Dzeko were injured. “Maybe nobody believed one or two months ago we can continue in Champions League and be involved in the fight for the title but we always trust in what we do and the way we work every day and that is why I am so happy the squad demonstrates why we won the title last year. “You do not win the title in December but it is a key month. “If you want to be involved and have a chance to win the title, you must be as near as you can be to the lead of the table.” When asked whether any of his strikers would be fit for City’s game at West Brom on Boxing Day, Pellegrini said: “I don’t think so.” Manuel Pellegrini was happy to see Manchester City move joint top of the table, but Neil Warnock was in a much darker mood following Crystal Palace’s 3-0 defeat at the Etihad Stadium. James McArthur’s effort was disallowed halfway through the second period even though he was played onside by City midfielder Fernandinho. “It was a disgraceful decision,” the Palace boss said. “The linesman was in a terrible position. “I don’t understand why top-class officials get it wrong like that. “There is no explanation for it. The linesman will be disappointed when he sees (a replay) but that’s no consolation to me. It was a game-changing decision. “You could tell the crowd were nervous. It could have been 2-1 with 20 minutes go but it’s a canter for them all because of that. “You have to do your job right if you are at the top level if you are a linesman. “It’s not hard to look over and see. It’s not even close, it’s miles onside.
Fourth of July will look a little different this year due to the pandemic.Many will be lighting fireworks, and now that hand sanitizer has become an essential for nearly everyone around the globe, it could make for a painful combination this Fourth of July when it comes to lighting fireworks.The NSC shared firework safety tips on nsc.org which include; leaving fireworks to the professionals, understand your state’s laws because each state is different, adults should never use fireworks while impaired by drugs or alcohol, never allow young children to handle fireworks.Because fireworks are apart of the celebration for Fourth of July, and now hand sanitizer is apart of people’s daily routines, experts warn people that hand sanitizer contains alcohol which is highly flammable. “Alcohol and fire do not mix,” National Safety Council (NSC) spokeswoman Maureen Vogel told CNN. “You shouldn’t pair flammable items; it’s the proverbial recipe for disaster.”Stay safe everyone, and Happy Fourth of July!